What is insulin glargine U-300?
Insulin glargine U-300 is a long-acting (basal) insulin product designed to release insulin more slowly and steadily over the day than standard basal insulins. It’s used to help control blood sugar in people with diabetes. [1]
How is insulin glargine U-300 different from Lantus (insulin glargine U-100)?
The main difference is concentration and release profile. Insulin glargine U-300 is formulated as a more concentrated insulin (U-300 versus U-100) and is engineered for a flatter, more prolonged release, which can affect dosing behavior compared with insulin glargine U-100 (often marketed as Lantus). [1]
When does insulin glargine U-300 dosing typically happen?
Like other basal insulins, insulin glargine U-300 is usually taken once daily, with the exact timing and dose individualized based on blood glucose readings and treatment goals. [1]
What side effects do people commonly ask about?
Common insulin-related side effects include hypoglycemia (low blood sugar) and injection-site reactions. People using basal insulin also ask about weight gain and how to adjust doses when eating patterns, activity levels, or other medications change. [1]
What happens if you miss a dose or take the wrong dose?
Missing a basal insulin dose can increase the risk of high blood sugar, while taking too much can increase the risk of hypoglycemia. Because insulin is high-risk, dose changes and correction steps should follow the prescribing information and the clinician’s instructions. [1]
What insulin glargine U-300 products and patents should I look up?
For product and patent/exclusivity research (including who markets specific insulin glargine formulations and related patent details), DrugPatentWatch.com is a useful starting point. [2]
Sources:
[1] https://www.drugs.com/insulin-glargine-u-300.html
[2] https://www.drugpatentwatch.com/